Affinity Biopharma is a global, clinical stage biopharmaceutical
company focused on advancing innovative technology and first-in-class
anti-tumor treatment. We have established our Tumor MicroEnvironment Activated (TMEA) platform
technology including TMEA-SMDC, TMEAbody®, TMEAkine®, TMEA-ICE®, ADC and TMEA-XDC
platforms, which allow selective unleash of the active drug in the tumor
microenvironment, solving “on target/ off tumor toxicity”, enhancing efficacy
at targeted sites and dramatically improving the therapeutic index.
Affinity Biopharma has built the tumor microenvironment activated,
intelligent platform for small molecule drugs and biologics. TMEA-SMDC (Small
Molecule Drug Conjugate) platform transforms the traditional chemotherapy,
target therapy and immune agonists into first-in-class, precision guided TMEA
cancer therapy, which could replace the original drug and is suitable to
combine with immunotherapy. Affinity Biopharma’s biologics platform (including TMEAbody®,
TMEAkine®, TMEA-ICE®, ADC and TMEA-XDC) conjugates cytokines, antibodies, immune
cell engagers, and fusion proteins to create new generation of innovative drugs
with global rights.
Affinity Biopharma was established in December
2011 and headquartered in Shanghai, China. We are a global originator, with
100% original pipeline and innovative drugs with global rights and proprietary
protection. Among
them, our first TMEA SMDC drug has entered Pivotal
(Phase II/III) trial. We aim to address the unmet medical needs, and
open up a new era of combination therapy.
Our
vision is as follows: “Compassionate and Innovative, Aim for Curative Therapeutic
Solution for Cancer Patients”. In the next 10 to 20 years, we look forward to
revolutionizing cancer treatment through innovative technology platform,
turning malignant tumors into chronic and controllable diseases with long-term
survival. To achieve this goal, we would actively carry out various forms of
cooperation and innovation with worldwide biopharmaceutical companies and
academic research institutions. In the meantime, through licensing and
strategic partners, we would be able to broaden our platform application and
bring greater values to patients and the whole society.
